¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"proliferating cell nuclear antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • polymerized antigen
    ÁßÇÕüÇ׿ø
  • polypeptide antigen
    Æú¸®ÆéƼµåÇ׿ø
  • polysaccharide antigen
    ´Ù´çüÇ׿ø
  • polyvalent antigen
    ´Ù°¡Ç׿ø
  • private antigen
    °³º°Ç׿ø
  • prostate specific antigen
    Àü¸³»ùƯÀÌÇ׿ø
  • protective antigen
    ¹æ¾îÇ׿ø
  • public antigen
    °øÀ¯Ç׿ø
  • particulate antigen
    ¹Ì¸³ÀÚÇ׿ø
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • residual antigen
    ÀÜ·ùÇ׿ø
  • soluble antigen
    °¡¿ë¼ºÇ׿ø
  • somatic antigen
    ±ÕüÇ׿ø
  • species-specific antigen
    Á¾Æ¯ÀÌÇ׿ø
  • specific antigen
    ƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • polymerized antigen
    ÁßÇÕüÇ׿ø
  • polypeptide antigen
    Æú¸®ÆéƼµåÇ׿ø
  • polysaccharide antigen
    ´Ù´çüÇ׿ø
  • polyvalent antigen
    ´Ù°¡Ç׿ø
  • private antigen
    °³º°Ç׿ø
  • protective antigen
    ¹æ¾îÇ׿ø
  • public antigen
    °øÀ¯Ç׿ø
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • residual antigen
    ÀÜ¿©Ç׿ø
  • self antigen
    ÀÚ±âÇ׿ø
  • sensitized antigen
    ¹Î°¨Ç׿ø
  • sequestered antigen
    °Ý¸®Ç׿ø
  • serologically defined antigen
    Ç÷ûÇÐÀû±ÔÁ¤Ç׿ø
  • soluble antigen
    ¼ö¿ë¼ºÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen competition
    Ç׿ø°æÀï.
  • antigen detection
    Ç׿ø°ËÃâ
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö(ù÷ê«üªß¤ßÈâ¦).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • outer nuclear layer
    ¹Ù±ùÇÙÃþ
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ÇÙ¼º¾È±Ù¸¶ºñ.
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ ÇÙ¼º ¾È±Ù¸¶ºñ(òäú¼àõ ú·àõ äÑÐÉØ¦Ýö)
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ÇÙ¼º¾È±Ù¸¶ºñ
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • beta cell insulin cell
    º£Å¸¼¼Æ÷ Àν´¸°¼¼Æ÷
  • bronchiolar cell clara cell
    ¼¼±â°üÁö¼¼Æ÷
  • cell to cell cooperation
    ¼¼Æ÷°£ÇùÁ¶ÀÛ¿ë(á¬øàÊàúððàíÂéÄ).
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • clear cell basal cell carcinoma
    Åõ¸í¼¼Æ÷ ±âÀú¼¼Æ÷¾Ï
  • clear cell epinephrine cell
    ¹àÀº¼¼Æ÷ ¿¡Çdz×ÇÁ¸°¼¼Æ÷
  • cytotoxic T-cell ; killer T-cell
    (¼¼Æ÷)»ì(ÇØ) T¼¼Æ÷.
  • dark cell norepinephrine cell
    ¾îµÎ¿î¼¼Æ÷ ³ë¸£¿¡Çdz×ÇÁ¸°¼¼Æ÷
  • interstitial cell dark cell
    »çÀÌÁú¼¼Æ÷
  • interstitial cell leydigs cell
    »çÀÌÁú¼¼Æ÷
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Endocrine cell of pineal gland
    ¼Û°úü³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Û°úü³»ºÐºñ¼¼Æ÷
  • Pinealocyte [Clear cell]
    ¼Û°úü¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Û°úü¼¼Æ÷
  • Horizontal cell
    ¼öÆò¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÆò¼¼Æ÷
  • Goblet cell
    ¼úÀܼ¼Æ÷
    [¿¾ ¿ë¾î] ¹è»ó¼¼Æ÷
  • Neurosensory epithelial cell
    ½Å°æ°¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ½Å°æ°¨°¢»óÇǼ¼Æ÷
  • Ganglion cell layer
    ½Å°æÀý¼¼Æ÷Ãþ
    [¿¾ ¿ë¾î] ½Å°æÀý¼¼Æ÷Ãþ
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] À§¼º¼¼Æ÷
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷ [À§¼º¼¼Æ÷]
    [¿¾ ¿ë¾î] ½Å°æÀý±³¼¼Æ÷
  • Satellite cell
    ½Å°æÀý¾Æ±³¼¼Æ÷ [À§¼º¼¼Æ÷]
    [¿¾ ¿ë¾î] À§¼º¼¼Æ÷
  • Cardiac muscle cell
    ½ÉÀå±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½É±Ù¼¼Æ÷
  • Glial cell
    ¾Æ±³¼¼Æ÷
    [¿¾ ¿ë¾î] ±³¼¼Æ÷
  • Glial cell process
    ¾Æ±³¼¼Æ÷µ¹±â
    [¿¾ ¿ë¾î] ±³¼¼Æ÷µ¹±â
  • Glial cell body
    ¾Æ±³¼¼Æ÷ü
    [¿¾ ¿ë¾î] ±³¼¼Æ÷ü
  • Ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Æ¸Þ¹Ù¾ç¼¼Æ÷
  • Dark cell
    ¾îµÎ¿î¼¼Æ÷
    [¿¾ ¿ë¾î] ¾Ï¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • COS cell
    COS ¼¼Æ÷(á¬øà)
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
  • double-sector cell
    ÀÌÁß±¸È¹½Ç(ì£ñìÏ¡üñãø)
  • effector cell
    È¿°ú±â ¼¼Æ÷(üùÍýÐïá¬øà)
  • enucleated cell
    Á¦ÇÙ ¼¼Æ÷ (ð¶ú·á¬øà)
  • established cell line
    ¼ö¸³ ¼¼Æ÷ÁÖ (â§Ø¡á¬øàñ»)
  • feeder cell
    °ø±ÞÀÚ¼¼Æ÷ (ÍêÐåíºá¬øà)
  • flow cell
    È帧 ½Ç(ãø)
  • founder cell
    ½ÃÁ¶ ¼¼Æ÷(ã·ðÓá¬øà)
  • germ cell
    ¹è¼¼Æ÷(ÛÏá¬øà)
  • germinal cell
    ¹è¾Æ¼¼Æ÷(ÛÏä´á¬øà)
  • glial cell
    ½Å°æ±³¼¼Æ÷(ãêÌèÎïá¬øà)
  • half-cell
    ¹Ý½Ç(Úâãø)
  • helper T cell
    µµ¿òÀÌ T ¼¼Æ÷(á¬øà)
  • host-cell reactivation
    ¼÷ÁÖ ¼¼Æ÷ ÀçȰ¼ºÈ­(âÖñ«á¬øàî¢üÀàõûù)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
Ts cell suppressor T cell(= T8 cell)
BC Bachelor of Surgery [Lat. Baccal-aureus Chirurgiae]; back care; bactericidal concentration; basal ce...
DRBC denaturated red blood cell; dog red blood cell; donkey red blood cell
EC effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme...
FLC family life cycle; fatty liver cell; fetal liver cell; Friend leukemia cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
SCC Squamous Cell Carcinoma Antigen
SCCA Squamous cell carcinoma antigen
SCC Ag Squamous cell carcinoma antigen
SCC-Ag Squamous cell carcinoma-related antigen
TCR T Cell Antigen Receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell lymphoma
    B ¼¼Æ÷ ¸²ÇÁÁ¾
    ¾Ç¼º ¸²ÇÁÁ¾ Áß¿¡¼­ ¥ì¼â, DR Ç׿ø, Leu-10ÀÇ B ¸²ÇÁ±¸ Ç¥½ÃÀÚ°¡ Áõ¸íµÈ ¸²ÇÁÁ¾ÀÌ´Ù. Áõ¸íµÈ Ç¥½ÃÀÚ´Â °³°³ÀÇ Áõ·Ê¿¡ µû¶ó ´Ù¸£°í ¥ì+, DR+ Leu-10+ÀÇ ÀüÇüÀûÀÎ ¿¹·ÎºÎÅÍ DR ³»Áö Leu-10¸¸ÀÌ ¾ç¼ºÀÎ Áõ·Ê¿¡ À̸£±â±îÁö ±× º¯È­´Â ´Ù¾çÇÏ´Ù. ÇüÅÂÀûÀÎ ºÐ·ù¿¡ ÀÇÇÑ °áÀý¼º ¸²ÇÁÁ¾, ¸²ÇÁÇüÁú ¼¼Æ÷¼º ¸²ÇÁÁ¾, ¹èÁ᫐ ¼¼Æ÷¿¡¼­ À¯·¡ÇÏ´Â ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾ µîÀÌ B¼¼Æ÷ ¸²ÇÁÁ¾¿¡ ¼ÓÇÑ´Ù.
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • B cell tolerance
    B ¼¼Æ÷ ³»¼º
    ¸é¿ªÇÐÀû ³»¼º »óÅ´ T ¼¼Æ÷¿¡µµ B ¼¼Æ÷¿¡µµ ¹ß»ý ¼ö ÀÖÁö¸¸ B ¼¼Æ÷ÀÇ ³»¼º »óÅ´ T ¼¼Æ÷¿¡ ºñÇÏ¿© ¹ß»ýÇϱⰡ ¾î·Æ´Ù. B ¼¼Æ÷¸¦ ³»¼º »óÅ·ΠÇÏ·Á¸é ÀϹÝÀûÀ¸·Î ´ë·®ÀÇ Ç׿øÀÌ ÇÊ¿äÇϰí Ç׿ø Åõ¿© ÈÄ¿¡ ³»¼º »óÅ·Πµé¾î°¡´Â µ¥µµ T ¼¼Æ÷º¸´Ù ¿À·£ ½Ã°£ÀÌ °É¸®°í ÀÏ´Ü ³»¼º »óÅ·Πµé¾î°¡µµ Áö¼Ó½Ã°£ÀÌ Âª°í °ð ÇØÁ¦µÇ¾î ¹ö¸°´Ù.
  • band cell
    ¶ì ¼¼Æ÷
  • basal cell
    ±âÀú ¼¼Æ÷, ±âÃÊ ¼¼Æ÷
    Ç¥ÇÇ ±âÀúÃþ¿¡ Á¸ÀçÇÏ´Â Ãʱâ ÄÉ¶óÆ¾ ¼¼Æ÷¸¦ ÀÏÄ´ À̸§. Æ÷À¯·ù Á¤¼ÒÀÇ ¼¼Á¤°ü ¼Ó¿¡¼­ ¿ÜÃø ±âÀú¸·¿¡ Á¢ÇÏ¿© »êÀçÇØ ÀÖ´Â ´ëÇü ¼¼Æ÷. ¼¼¸£Å縮 ¼¼Æ÷
  • basal cell adenocarainoma
    ±âÀú ¼¼Æ÷ ¼±¾Ï
    ¸Å¿ì µå¹°°í ±âÀú ¼¼Æ÷ ¼±Á¾ÀÇ ¾Ç¼ºÀÌ´Ù. ¿Ü°úÀû ÀýÁ¦ ½Ã ¿¹Èİ¡ ÁÁ´Ù.
  • basal cell carcinoma
    ±âÀú ¼¼Æ÷ ¾Ï, ±âÀú ¼¼Æ÷ ¾ÏÁ¾
    1. »óÇÇÀÇ ±âÀú ¼¼Æ÷¸¦ ´àÀº ±âº» ±¸Á¶¸¦ °¡Áö´Â »óÇÇ ¼¼Æ÷ ½Å»ý¹°. À̰ÍÀº »óÇÇ ¼¼Æ÷ÀÇ ±âÀú ¼¼Æ÷, ¸ð³¶À̳ª ÇÇÁö¼±ÀÇ ¿Ü¹æ ¼¼Æ÷, ƯÈ÷ ¾È¸éÀÇ °¡¿îµ¥ 1/3¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô ÀüÀ̵ÇÁö¸¸ ±¹¼ÒÀûÀ¸·Î ħ¹üÇÑ´Ù. ±¸°­ Á¡¸·¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê´Â´Ù. Çѱ¹ÀÎ ÇǺΠ¾Ç¼º Á¾¾ç Áß °¡Àå ¸¹Àº ÇüÀÌ´Ù. ÀüÀ̰¡ Àß ¾ÈµÇ¸ç Àç¹ßÀ²ÀÌ ÀûÀº Áß°£ ¾Ç¼ºµµÀÌ´Ù. ±¸°­ÀÇ ±âÀú ¼¼Æ÷ ¸ð¹Ý ÁõÈıº°ú °ü·ÃÀÌ ÀÖ´Ù. 2. Ç¥ÇÇ ±âÀúÃþÀÇ ¾Ç¼º Á¾¾ç.
  • basal cell epithelioma
    ±âÀú ¼¼Æ÷ »óÇÇ ¾Ï, ±âÀú ¼¼Æ÷ »óÇÇÁ¾
    Áß³â ÀÌÈÄ¿¡ »ý±â±â ½±°í ±× ŹÝÀÌ ¾È¸é ÇǺο¡ ¹ß»ýÇÑ´Ù. Ãø»öÀÇ ¼Ò°áÀýÀÌ Áý»êÇÑ Á¾¾çÀ» Çü¼ºÇϴµ¥ ¹Ý±¸»óÀ¸·Î À¶±âÇÏ´Â °Í, ÆíÆòÇÑ ¹Ý»óÀÇ ÆÛÁü µî ¿©·¯ °¡ÁöÀÌ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â ÇǺΠǥÇÇ ±âÀú ¼¼Æ÷ÀÇ Áõ½ÄÀÌ°í ¼¼Æ÷ ºÐ¿­, ÀÌÇü¼º µîÀº °ÅÀÇ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • basal cell hyperplasia
    ±âÀú ¼¼Æ÷ °úÇü¼º
  • basal cell nevus
    ±âÀú ¼¼Æ÷ ¸ð¹Ý
  • basal cell papilloma
    ±âÀú ¼¼Æ÷ À¯µÎÁ¾
  • basal-cell layer
    ±âÀú ¼¼Æ÷Ãþ
  • basophilic cell
    È£¿°±â¼º ¼¼Æ÷
  • basosqumaous cell acanthoma
    ±âÀú ÆíÆò ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
antigen-presenting cells Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation.
(12 Dec 1998)
antigen processing Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell.
(18 Nov 1997)
antigen shift Abrupt change in antigens expressed by a species or variety of organisms. Usually seen in microorganisms where the change may allow escape from immune recognition. Antigenic drift is a more gradual change.
See: antigenic variation.
(18 Nov 1997)
antigen unit The smallest amount of antigen that, in the presence of specific antiserum, will fix 1 complement unit.
(05 Mar 2000)
aspergillus antigen skin test <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis.
(27 Sep 1997)
Au antigen Auberger blood group
Aus antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
Australia antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
becker antigen bea antigen
blood group antigen <haematology, immunology> The set of cell surface antigens found chiefly, but not solely, on blood cells.
More than fifteen different blood group systems are recognised in humans. There may be naturally occurring antibodies without immunisation, especially in the case of the ABO system and matching blood groups is important for safe transfusion.
In most cases the antigenic determinant resides in the carbohydrate chains of membrane glycoproteins or glycolipids.
See: Rhesus, Duffy, Kell, Lewis and MN.
(25 Jun 1999)
cancer antigen 125 test Test for cell-surface antigen found on derivatives of coelomic epithelium. Elevated levels of this antigen are associated with ovarian malignancy and benign pelvic disease such as endometriosis.
(05 Mar 2000)
capsular antigen That found only in the capsules of certain microorganisms; e.g., the specific polysaccharides of various types of pneumococci.
(05 Mar 2000)
carcinoembryonic antigen <tumour marker> Antigen found in blood of patients suffering from cancer of colon and some other diseases, that is otherwise normally found in foetal gut tissue.
(19 Jan 1998)
macrophage-1 antigen An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b antigen and the beta subunit of the CD18 antigen (antigens, CD18). The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
V antigen Viral antigen that is intimately associated with the virus particle, is protein in nature, has multiple antigenicities, and is strain-specific; antibody to such antigen is demonstrable as protective or neutralizing antibody.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á